


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 22, 2009.



Frank C. Eisenschenk, Ph.D., Patent Attorney

Patent Application
Docket No. C.R.107
Serial No. 10/539,847

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Chih Min Kam
Art Unit : 1656
Applicants : Richard Joseph Fagan, Christopher Benjamin Phelps, Christine Power, Richard James Mitter, Ursula Boschert, Yolande Chvatchko
Serial No. : 10/539,847
Filed : June 20, 2005
Conf. No. : 5016
For : Metalloprotease Proteins

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

The Notice to File Corrected Application Papers mailed April 8, 2009 indicates that replacement drawings in compliance with 37 CFR 1.84 and 37 CFR 1.21(d) are required in the above-referenced patent application. Specifically, Figures 10 and 13 are not acceptable because they are continued over several pages without proper labeling.

Transmitted herewith are replacement pages 11/18 (continuation of Figure 10) and 15/18 (continuation of Figure 13). In addition, Applicants have submitted replacement page 5/18 (Figure 5) because the consensus polyadenylation site was in red and was illegible. The consensus polyadenylation site is now underlined. Replacement page 14/18 (Figure 13) has also been replaced to underline the active sites which were previously highlighted.

I hereby certify that the paper copy as filed and the replacement drawing sheet contain the same information and that no new material is added or deleted by this submission.

The Commissioner is hereby authorized to charge any additional fees which may be required to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Replacement pages 5/18 (Figure 5), 11/18 (Figure 10 continuation), 14/18 (Figure 13) and 15/18 (Figure 13 continuation).